Magnet Biomedicine, a leading biopharmaceutical company advancing molecular glue discovery with rational selection and design ...

The molecular glue wave that first began years ago is still swelling, with Eli Lilly earmarking approximately $1.65 billion ...

Eli Lilly (LLY) joins hands with Magnet Biomedicine in a deal worth up to $1.25B to develop cancer drugs using Magnet's ...

Magnet Biomedicine, a biopharmaceutical company advancing molecular glue discovery, has entered a collaboration and license ...

The molecular glue space has attracted several Big Pharma players over the past few years, including Novo Nordisk, Pfizer and ...

Thermo Fisher Scientific is buying Solventum‘s purification and filtration business for $4.1 billion. Magnet Bio and Eli Lilly entered into a collaboration that could reach $1.25 billion in value.

Eli Lilly plans to spend at least $27 billion to build four new manufacturing plants in the U.S., the drugmaker said at a ...

Eli Lilly has acquired Organovo’s lead asset, a clinical FXR agonist designed to treat inflammatory bowel disease (IBD), in a ...

U.S. Secretary of Commerce Howard Lutnick said Lilly was doing "exactly what the President was hoping would happen." ...